Clinical Trial: Efficacy and Safety of Telitacicept in the Treatment of Refractory Rheumatoid Arthritis

U.S., Sept. 2 -- ClinicalTrials.gov registry received information related to the study (NCT07796516) titled 'Efficacy and Safety of Telitacicept in the Treatment of Refractory Rheumatoid Arthritis' on Aug. 27.

Brief Summary: This study is a multicenter, open-label, randomized controlled trial designed to preliminarily evaluate the efficacy and safety of telitacicept in patients with refractory rheumatoid arthritis during a 24-week treatment period followed by a 2-week follow-up period.

Study Start Date: Sept. 01

Study Type: INTERVENTIONAL

Condition: Difficult-to-treat Rheumatoid Arthritis Rheumatoid Arthritis

Intervention: BIOLOGICAL: Telitacicept 160mg

Telitacicept 160 mg will be administered subcutaneously once weekly for 24 conse...